## **Expanded View Figures**



## Figure EV1. Overlap of pPDH and LEF1 spots in xenograft tumors.

Convex hull image analysis of serial sections of SW480 mock xenograft tumors stained for pPDH and LEF1, as shown in Fig 1A and B, second panels.

A, B Isolated contour maps with convex hull outlines for pPDH and LEF1.

C-E pPDH and LEF1 contour maps were overlaid on each other and overlapped regions highlighted in blue. Different thresholds for spot detection were tested; each threshold condition revealed between 65 and 77% overlap between pPDH and LEF1 spots.

F Summary of overlap results.



## **Figure EV2.** What **ligand and glycolysis gene expression in rectal cancer patients post-radiochemotherapy.** Gene expression data, from GEO dataset GDS3756, of 21 rectal cancer patients before and after radio-chemotherapy (Snipstad *et al*, 2010).

- A, B Expression of Wnt ligands WNT5B, WNT8B, and WNT10B shows trends toward increased expression in rectal tumor tissue treated with radiochemotherapy, but these changes do not reach statistical significance when *P* < 0.05 is used as a cutoff (specific *P*-values are 0.10, 0.10, and 0.08, respectively). Statistical significance was determined using the Mann–Whitney *U*-test with Benjamini–Hochberg correction for multiple hypothesis testing.
- C, D Expression of the glycolytic enzyme ENO2 is specifically increased in tumor tissue after radiochemotherapy (P = 0.008); HIF1A expression also shows a trend in increased expression (P = 0.06). \* denotes adjusted *P*-value < 0.05; + denotes adjusted *P*-value < 0.10. Statistical significance was determined using the Mann–Whitney *U*-test with Benjamini–Hochberg correction for multiple hypothesis testing.

## Figure EV3. Targeted therapy simulations for $P_{\rm g}$ and $P_{\rm o}$ populations.

Figure 5 gives the results for total tumor size after individually targeting either  $P_g$  or  $P_o$  cells with given treatment doses and treatment times. Here are the effects for the individual  $P_g$  and  $P_o$  populations in those targeted therapy simulations. Simulations suggest that the glycolytic cell population is a more sensitive drug target than the oxidative cell population. We target either  $P_o$  (left) or  $P_g$  (right) cells selectively, starting from a metabolically patterned state, for 2.5, 5, or 7.5 (arbitrary) time units, with a death rate between 0.25 and 1. After therapy is stopped, the cells are allowed to evolve according to the original model (Fig 2). The  $P_g$  and  $P_o$  cell populations, relative to their initial cell populations, are shown.



Figure EV3.